CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. announced Myriam Mendila as Chief Development Officer. Myriam Mendila has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including commercial strategy at Roche, Genentech and Novartis. Over the last 5 years, she has held the position of Chief Medical Officer of Oncology and Global Head of Oncology Medical Affairs at Novartis.

CureVac is a global biopharmaceutical company with more than 20 years of experience in developing the mRNA technology for medical purposes.